Loading...
Loading...
This company in Healthcare sector has seen a flat track record when it comes to current year estimate revisions over the past few weeks. The consensus for earnings hasn't changed either. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future, and especially on earnings estimates following the recent slump.
GERN currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.
Some better-ranked stocks in the same space include Alexion Pharmaqceuticals, Inc. ALXN, Alkermes plc ALKS and Gilead Sciences Inc. GILD. All these stocks carry a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
ALKERMES INC ALKS: Free Stock Analysis Report
ALEXION PHARMA ALXN: Free Stock Analysis Report
GERON CORP GERN: Free Stock Analysis Report
GILEAD SCIENCES GILD: Free Stock Analysis Report
To read this article on Zacks.com click here.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in